AVIEW LCS vs FFRct
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both AVIEW LCS and FFRct are AI-powered solutions in the Cardiology AI and Radiology & Imaging AI categories, offering FDA-cleared, HIPAA-compliant tools. AVIEW LCS provides a comprehensive cardiopulmonary assessment, including lung nodule detection, COPD analysis, and coronary artery calcification scoring from low-dose CT scans. FFRct, however, specializes in the non-invasive functional assessment of coronary artery disease by analyzing blood flow and creating 3D models from CCTA scans, making it suitable for detailed CAD diagnosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
AVIEW LCS is an AI-powered solution focused on the detection and analysis of lung nodules, lung cancer screening, COPD, and coronary artery calcification from a single low-dose CT scan. FFRct, on the other hand, is a non-invasive AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease.
AVIEW LCS utilizes low-dose CT scans for its analysis of lung and cardiopulmonary conditions. FFRct requires CCTA (Coronary CT Angiography) scans to generate its personalized 3D models and assess coronary artery blood flow.
AVIEW LCS provides automated lung nodule detection and analysis, Lung-RADS classification, nodule volume quantification, emphysema quantification, and coronary artery calcification (CAC) scoring. FFRct analyzes blood flow and identifies areas of narrowing by generating FFRct values and personalized 3D digital models of coronary arteries.
AVIEW LCS supports a broader range of specialties including Cardiology, Oncology, Pulmonology, and Radiology. FFRct is primarily focused on Cardiology and Radiology, specifically for the diagnosis of coronary artery disease.
For AVIEW LCS, pricing information requires direct contact with the company. For FFRct, there is a specified CMS payment rate of $1,017 for 2025, though commercial payer rates may vary.